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Abstract
Background:  Lysosomal storage diseases are characterized by intracellular accumulation of
metabolites within lysosomes. Recent evidence suggests that lysosomal storage impairs autophagy
resulting in accumulation of polyubiquitinated proteins and dysfunctional mitochondria, ultimately
leading to apoptosis. We studied the relationship between lysosome storage and impairment of
different intracellular pathways and organelle function in mucopolysaccharidosis VI, which is
characterized by accumulation of dermatan sulfate and signs of visceral and skeletal but not cerebral
involvement.
Results: We show lysosomal storage, impaired autophagy, accumulation of polyubiquitinated
proteins, and mitochondrial dysfunction in fibroblasts from mucopolysaccharidosis VI patients. We
observe similar anomalies, along with inflammation and cell death, in association with dermatan
sulfate storage in the visceral organs of mucopolysaccharidosis VI rats, but not in their central
nervous system where dermatan sulfate storage is absent. Importantly, we show that prevention
of dermatan sulfate storage in the mucopolysaccharidosis VI rat visceral organs by gene transfer
results in correction of abnormal autophagy, inflammation, and apoptosis, suggesting that dermatan
sulfate accumulation impairs lysosomal ability to receive and degrade molecules and organelles
from the autophagic pathway, thus leading to cell toxicity.
Conclusion:  These results indicate that the non-lysosomal degradation pathways we found
activated in mucopolysaccharidosis VI can be both targets of new experimental therapies and
biomarkers for follow-up of existing treatments.
Background
Lysosomal storage diseases (LSDs) are severe disorders
mostly inherited as autosomal recessive traits in which a
lysosomal enzyme defect causes intracellular accumula-
tion of cellular debris within the lysosomes [1]. Little is
known about the molecular pathways underlying pathol-
ogy in LSDs. Degradation and recycling of the building
blocks of organelles, proteins, and other cytoplasm com-
ponents is required for the maintenance of cellular home-
ostasis [2]. Two general mechanisms are used for large-
scale degradation of components of the cytoplasm; short-
lived regulatory proteins are degraded via the ubiquitin-
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proteasome system, and long-lived structures and pro-
teins are targeted to the lysosome by autophagy [2]. Sev-
eral forms of autophagy have been described [3]. In
macroautophagy, henceforth referred to as autophagy,
double-membrane vesicles called autophagosomes
sequester part of the cytoplasm and then fuse with lyso-
somes to form hybrid-like organelles called autophagolys-
osomes [3]. Several proteins are implicated in the
formation of autophagosomes. Beclin-1 (BCN1, homo-
logue of yeast ATG6), a protein of the Class III phosphati-
dylinositol 3 kinase (PI3K) complex, mediates autophagy
induction [2]. The microtubule-associated protein 1 light
chain 3 (LC3I, homologue of yeast ATG8) is cleaved at its
carboxy-terminal, and further modified to the lipid-conju-
gated LC3II, which is associated to autophagosome mem-
branes [2,4]. In particular, the ratio between the two
forms of LC3 (measured as LC3II/LC3I) correlates with
the number of autophagosomes [4]. Perturbation of
autophagy (that is, blocking of the fusion of autophago-
somes to lysosomes, or an increased number of
autophagosomes) results in prolonged nutrient starva-
tion, accumulation of toxic intracellular ubiquitin-related
protein aggregations which contain polyubiquitinated
proteins, and the critical multifunctional protein p62/
A170/sequestosome1 (SQSTM1; hereafter referred to as
p62) [5,6], and dysfunctional mitochondria, ultimately
leading to over-production of reactive oxygen species
(ROS), inflammation, and cell death [7]. Abnormal
autophagy has been described in human skin fibroblasts
and mice models of LSDs, such as Niemann-Pick C1
(NPC1) [8], Danon disease [9], neuronal ceroid lipofusci-
nosis 2 [10], Pompe disease [11], mucolipidosis type IV
[12-14], multiple sulfatase deficiency [15], mucopolysac-
charidosis type IIIA [15], and GM1 gangliosidosis [16],
indicating that LSDs might be considered as 'disorders of
autophagy'. Recently, a model has been proposed suggest-
ing that lysosomal accumulation of undegraded sub-
strates results in defective fusion between
autophagosomes and lysosomes [15,17], which, in turn,
leads to a progressive accumulation of poly-ubiquitinated
protein aggregates and of dysfunctional mitochondria,
eventually leading to cell death [17,18]. However, the evi-
dence that substrate accumulation is the primary media-
tor of these anomalies is still missing.
Mucopolysaccharidosis VI (MPS VI), also known as Maro-
teaux-Lamy syndrome, is caused by deficiency of the lyso-
somal enzyme N-acetylgalactosamine-4-sulfatase
(arylsulfatase B, ARSB) [19]. ARSB hydrolyzes sulfate
esters from glycosaminoglycans, mainly dermatan sulfate
(DS). ARSB deficiency prevents the sequential degrada-
tion of DS leading to its accumulation in various cells and
tissues [19]. Clinically, MPS VI is characterized by coarse
faces, short stature, dysostosis multiplex, stiffness and
functional impairment of joints, hepatosplenomegaly,
cardiac valve anomalies and corneal clouding [19]. No
clinical signs of central nervous system (CNS) involve-
ment are evident in clinically severe MPS VI [20]. Sponta-
neous animal models of MPS VI, which closely resemble
the human disease, have been described in cats [21], dogs
[22], and rats [23]. In agreement with the absence of CNS
disease in patients, MPS VI animal models do not show
behavioral anomalies nor significant DS accumulation in
CNS, although some ultrastructural anomalies in MPS VI
cat neurons have been reported [24]. Taking advantage of
the difference in storage in visceral organs versus CNS of
MPS VI and of the possibility to revert storage by gene
transfer, we have studied the relationship between storage
and autophagy, polyubiquitination, mitochondrial func-
tion, inflammation and apoptosis in MPS VI cells and tis-
sues.
Results
Storage accumulation leads to impaired autophagy, 
abnormal protein ubiquitination and mitochondrial 
function in human MPS VI cells
We hypothesized that excessive DS accumulation alters
the lysosomal ability to degrade cytoplasmic components
or organelles through autophagy. To test this we initially
used primary skin fibroblasts from three controls (normal
fibroblasts, NR) and seven MPS VI patients. Measure-
ments of DS accumulation via the quantitative dimethyl-
methylene blue method showed significantly higher DS
levels in MPS VI cells than in NR cells (Figure 1A). We
then sought to determine whether abnormal autophagy
occurs in MPS VI cells by analyzing LC3 levels. Western
blot analyses of protein lysates from skin fibroblasts
showed increased levels of LC3II in MPS VI compared
with NR fibroblasts (Figure 1B and 1D), indicating accu-
mulation of autophagosome proteins. Furthermore, con-
focal microscopy analysis confirmed increased numbers
of LC3-positive vesicles in MPS VI compared with NR
fibroblasts (Figure 1E) some of which colocalized with the
lysosomal marker, lysosome-associated membrane pro-
tein-2 (LAMP2), as indicated by the presence of yellow
signal in the merged panel (Figure 1E, see also insert). Our
data show that the extent of LAMP2/LC3 colocalization is
similar between MPS VI and NR fibroblasts, thus suggest-
ing that autophagosome-lysosome fusion is not com-
pletely blocked in MPS VI fibroblasts (Figure 1E). To
understand whether the increase in autophagic markers
observed in MPS VI cells is due to the deficient ability of
lysosomes to recycle metabolites, we compared the Epi-
dermal Growth Factor (EGF)/EGF Receptor (EGFR) turn-
over in MPS VI and NR fibroblasts based on the
knowledge that binding of EGF to EGFR induces ubiquiti-
nation, rapid internalization and degradation of both lig-
and and receptor via the lysosomal pathway [25,26].
Loading of EGF on NR fibroblasts resulted in its almost
complete clearance in less than two hours, while EGF sig-PathoGenetics 2009, 2:4 http://www.pathogeneticsjournal.com/content/2/1/4
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nal was still persistent in MPS VI fibroblasts three hours
after loading (Figure 1F). These results were additionally
confirmed by time lapse analysis of NR and MPS VI
fibroblasts loaded with both EGF and lyso-tracker; EGF
delivery to lysosomes and subsequent degradation was
slower in MPS VI compared with NR fibroblasts (Addi-
tional files 1 and 2). These results suggest that lysosomal
ability to recycle metabolites is impaired in MPS VI pre-
sumably resulting in accumulation of autophagosomes.
We then postulated that impaired autophagy observed in
MPS VI fibroblasts could in turn result in accumulation of
ubiquinated proteins similarly to what has been observed
in other LSDs [10,13-15]. Western blot analysis with anti-
ubiquitin antibodies of fibroblast lysates showed
increased ubiquitin levels in MPS VI cells when compared
with NR cells (Figure 1C and 1D). Ubiquitin was accumu-
lated in ubiquitin-positive inclusions as assessed by
immuno-fluorescence analysis (Figure 1G). The accumu-
Impaired autophagy, increased polyubiquitination and dysfunctional mitochondria in human MPS VI fibroblasts Figure 1
Impaired autophagy, increased polyubiquitination and dysfunctional mitochondria in human MPS VI fibrob-
lasts. (A) Protein extracts from fibroblasts of three controls (NR fibroblasts) and of seven MPS VI patients (MPS VI fibrob-
lasts) were assessed for glycosaminoglycans (GAGs) accumulation by the quantitative dimethyl-methylene blue method (GAG 
levels are expressed as μg per mg of proteins: μg GAG/mg prot). (B and C) Representative western blot analysis of total 
lysates from NR and MPS VI fibroblasts blotted with anti-BCN1, -LC3, -p62, -COX IV (B) and -ubiquitin antibodies (C). Nor-
malization of protein loading was performed using anti-actin antibodies (B) and is the same for both panels B and C. (D) Quan-
tification of western blot analyses from three independent experiments (mean ± standard error). Values are expressed as fold 
of increase compared with NR fibroblasts (NR = 1). (E) Confocal images of NR and MPS VI fibroblasts stained with anti-LC3 
(green) and anti-LAMP2 (red) antibodies. Inserts illustrate the colocalization of the two proteins (merge panel). Magnification: 
63×. (F) Clearance of loaded Alexa Fluor 488-labeled EGF at various time points (T0, T30, T60, T120 and T180 = 0 min, 30 
min, 1 h, 2 h, and 3 h after loading, respectively). Magnification: 100×. (G) Human NR and MPS VI fibroblasts were labeled with 
anti-ubiquitin, -p62 and -COX IV antibodies. Magnification: 63×. (H) Measurement of mitochondria membrane potential by 
flow cytometry analysis of NR and MPS VI fibroblasts after loading with DiOC6 and propidium iodide (PI). All experiments 
were performed in triplicate. *P ≤ 0.05, **P ≤ 0.02, ***P ≤ 0.01.PathoGenetics 2009, 2:4 http://www.pathogeneticsjournal.com/content/2/1/4
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lation of ubiquitinated proteins in MPS VI cells occurred
in the presence of normal proteasome function as demon-
strated by the in vitro analysis of proteasome activity (data
not shown). This suggests that the increased ubiquitin lev-
els detected are secondary to the defective autophagy
observed rather than to a primary proteasome impair-
ment. In agreement with this finding, we found signifi-
cant p62 accumulation in MPS VI fibroblasts compared
with NR by both western blot and immuno-fluorescence
analyses (Figure 1B, D, and 1G). To test whether impaired
lysosomal function in MPS VI fibroblasts affects
autophagy of mitochondria, resulting in accumulation of
dysfunctional mitochondria, we measured the levels of
the mitochondrial marker COX IV by western blot and by
immuno-fluorescence analyses in MPS VI fibroblasts and
found it increased compared with controls (Figure 1B, D,
and 1G). In addition, using the mitochondria-specific
voltage dependent dye DiOC6 [27] we detected a reduc-
tion in the mitochondrial membrane potential in MPS VI
compared with NR fibroblasts in both normal (data not
shown) and starved conditions (Figure 1H), measured as
increase in DiOC6 fluorescence (from 23 ± 2.5% in NR
cells to 56.9 ± 4.2% in MPS VI cells, P = 0.05). These
results imply volume changes in MPS VI mitochondria,
indicating that they are dysfunctional. Finally, the modest
increase in BCN1 levels (Figure 1B and 1D) observed in
MPS VI fibroblasts suggests a positive feedback on
autophagy triggered by the inability of lysosomes to
receive and degrade macromolecules from the autophagic
membrane-trafficking pathway.
Dermatan sulfate accumulation in visceral organs of MPS 
VI rats results in abnormal autophagy, ubiquitination, 
mitochondrial function, inflammation, and apoptosis
To confirm the results observed in MPS VI human fibrob-
lasts in vivo we studied a rat model of MPS VI which shows
severe signs of visceral and skeletal but not of CNS
involvement. We observed that in vivo DS accumulates in
peripheral tissues. Storage was detected in liver, spleen,
and kidney using toluidine blue staining of semi-thin sec-
tions (Figure 2A, arrows) and using the quantitative dime-
thyl-methylene blue assay (Figure 2B). We then tested
whether DS accumulation in lysosomes correlates with
abnormal autophagy in MPS VI rat tissues. Electron-
microscopy analysis of liver sections from 6-month-old
normal (NR) and MPS VI affected (AF) rats revealed a
higher number of autophagic vacuoles (AVs) in AF rat sec-
tions compared with NR (Figure 3A). The autophagic vac-
uoles appear as double-layered vacuoles encircled by ER-
like membrane saccules, and contain cytoplasmic
organelles together with part of the cytoplasm. AV mor-
phology showed abnormal autophagic figures, with vari-
ous morphologic features reflecting different stages of the
disease [28,29]. Some AVs (arrowheads) showed normal
appearance similar to that observed following autophagy
induction when no impairment of autophagosome-lyso-
some fusion occurs [28,29]. Other AVs (x symbols) have
organellar structures accumulated within swollen vescicu-
lar compartments, which is typical of AVs formed after a
short exposure to drugs which block autophagy [28,29].
This observation may reflect a later stage of the disease
when impairment in autophagosome-lysosome fusion
occurs because of the inability of the engulfed lysosomes
to degrade their content. Finally, if metabolites persist in
AVs for long enough, their content becomes electron-
dense and compact (black arrows) [28,29]. Similarly to
that observed in MPS VI human fibroblasts, western blot
analyses of liver, spleen, and kidney lysates demonstrate
increased levels of LC3II (Figure 3B and 3C) in AF com-
Glycosaminoglycan (GAG) accumulation in visceral organs of  MPS VI rats Figure 2
Glycosaminoglycan (GAG) accumulation in visceral 
organs of MPS VI rats. (A) Toluidine blue staining of 
semi-thin sections (1 μm thick) shows vacuoles filled with 
storage (arrows) in lysosomes of cells from liver, spleen, and 
kidney of 6-month-old MPS VI affected (AF) rats, which were 
absent in the same tissues of normal (NR) rats. Magnification: 
100×. (B) Quantitative measurement of GAG accumulation 
via dimethyl-methylene blue method on tissue lysates from 
liver, spleen, and kidney of AF and NR rats. (GAG levels are 
expressed as μg per mg of proteins: μg GAG/mg prot). *P ≤ 
0.01.
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pared with NR rat tissues, possibly indicating that lyso-
somal accumulation of DS results in impairment of the
autophagic pathway and in accumulation of AVs in vivo.
In addition, increased levels of ubiquitin and of p62, as
detected by western blot (Figure 3B and 3C) and by
immune-histochemistry (Figure 3D) or immuno-fluores-
cence (Figure 3E) analyses, suggest the formation of intra-
cellular ubiquitin-aggregates as consequence of impaired
autophagy. Accordingly, increased levels of COX IV, meas-
ured by western blot analysis, suggest the accumulation in
visceral AF organs of mitochondria (Figure 3B and 3C),
some of which appeared damaged, as evidenced by the
abnormal deposition of electron-dense multilayered
material (Figure 3A, both arrowheads, for mitochondria
included in AVs, and asterisks). Similarly to that observed
in MPS VI fibroblasts, a slight elevation in BCN1 levels
(Figure 3B and 3C) suggests a positive feedback on
autophagy induced by lysosome overloading.
We then asked whether engulfment of cells, due to DS
accumulation and impaired AV recycling, results in activa-
tion of inflammation and eventually in cell death. Abun-
dant CD68-positive monocyte/macrophage cells were
detected via immuno-histochemical analysis of 6-month-
old liver, spleen, and kidney sections of AF compared with
NR rats (Figure 4A and [30]). We also performed TUNEL
assay in the same sections detecting apoptotic cells in AF
rats, which were almost completely absent in NR rats (Fig-
ure 4B and 4C and [30]).
MPS VI rats, similarly to patients, do not show signs of
CNS involvement, strongly suggesting that substrate accu-
mulation does not occur in this organ. This provides the
unique opportunity to determine whether the abnormal
pathways observed in MPS VI visceral organs only occur in
the presence of DS accumulation and therefore to assess
whether the phenotype observed in cells and affected
organs is due to lysosomal storage. We initially measured
DS accumulation and the presence of vacuolated cells in
CNS of 6-month-old MPS VI rats. Quantitative measure-
ment using the dimethyl-methylene blue method showed
comparable levels of DS in CNS of AF and NR rats (Figure
5A). Similarly, electron microscopy (data not shown) and
toluidine blue staining of semi-thin brain sections from
either AF or NR rats (Figure 5B) did not show the presence
of cellular vacuolization. Consistent with absence of CNS
lysosomal storage, western blot analysis of brain lysates
revealed normal BCN1, LC3II, ubiquitin, and COX IV lev-
els, indicating normal autophagy, ubiquitination, and
mitochondrial function in neuronal MPS VI cells (Figure
5C). Immuno-histochemical analysis using anti-ubiquitin
antibodies as well as immuno-fluorescence analysis using
anti-p62 antibodies showed normal patterns of expres-
sion in CNS of AF rats (data not shown). Similarly, no
CD68 and TUNEL positive cells were detected in CNS of
either AF or NR rats (Figure 5D and 5E, respectively).
These data clearly indicate that the presence of abnormal
degradation pathways, inflammation, and apoptosis is
strongly associated with lysosomal storage in MPS VI tis-
sues. To additionally prove that DS storage is upstream of
the abnormalities observed in visceral organs in vivo, we
tested, using somatic gene transfer, whether DS clearance
Impaired autophagy, increased polyubiquitination and dys- functional mitochondria in visceral organs of MPS VI rats Figure 3
Impaired autophagy, increased polyubiquitination 
and dysfunctional mitochondria in visceral organs of 
MPS VI rats. (A) Electron-microscopic analysis of liver cells 
from 6-month-old normal (NR) or affected (AF) rats. 
Arrows, arrowheads and 'x' symbols point at autophagic 
vescicles (AVs) with different morphology (see Results for 
description). Asterisks indicate accumulated mitochondria 
with altered morphology, which are sometimes included in 
AVs. Scale bars = 2.2 μm. (B) Representative western blot 
analysis of tissue lysates from NR and AF rat liver, spleen, 
and kidney blotted with anti -BCN1, -LC3, -ubiquitin, -p62, -
COX IV and -actin antibodies. (C) Quantification of western 
blot analyses. Values are expressed as fold of increase com-
pared with NR rat tissues (NR = 1), and are the mean ± 
standard error of three independent experiments. (D) 
Immuno-histochemical analysis with anti-ubiquitin antibodies 
and (E) immuno-fluorescence analyses with anti-p62 anti-
bodies of liver, spleen, and kidney sections from 6-month-old 
NR and AF rats. Magnification 100×. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.005.PathoGenetics 2009, 2:4 http://www.pathogeneticsjournal.com/content/2/1/4
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rescues the phenotype observed thus resulting in the nor-
malization of autophagy, ubiquitination, mitochondrial
function, and ultimately inflammation and apoptosis in
the affected tissues of AF rats. We recently reported that
systemic administration of adeno-associated viral (AAV)
vectors expressing ARSB in newborn MPS VI rats results in
therapeutic levels of circulating ARSB and in a significant
decrease of DS storage in visceral organs [30]. Using the
same protocol described in [30], MPS VI rats were injected
at birth (post-natal day 3 to 5) with 4.1 × 1013 genome
copies/kg of AAV2/8 TBG-ARSB in the temporal vein
(indicated as TR). Six months after injection rats were sac-
rificed and tissues collected for analysis. Controls
included age-matched NR and non-treated AF rats. In
order to assess impaired autophagy, ubiquitination, and
mitochondrial dysfunction we analyzed the levels of
marker proteins (BCN1, LC3II, ubiquitin, p62, and COX
IV). Western blot analyses of liver (Figure 6A and 6B),
spleen, and kidney lysates (data not shown) from NR and
TR animals showed normal levels of all markers tested as
opposed to AF lysates. These results indicate that storage
reduction normalizes lysosomal-associated alterations,
indicating that the molecules studied can be used as
biomarkers to assess the efficacy of preventive and thera-
peutic interventions.
Discussion
Despite the differences in the type and the amount of
metabolites accumulated in LSDs as well as the cells or tis-
sues where storage occurs, the clinical and pathological
manifestations are to some extent similar among LSDs,
thus suggesting common mechanisms of disease triggered
by different genetic defects [8-16,30-36]. Identification of
critical cellular mediators within these processes may help
develop therapies to target them and biomarkers for fol-
low-up of disease progression and therapeutic interven-
tion.
A growing body of evidence suggests that lysosomal stor-
age leads to reduced functionality of lysosomes and con-
sequent autophagy deregulation [15-17]. In this study, we
showed impaired autophagy with increased levels of
autophagic proteins, increased polyubiquitination and
abnormal mitochondrial function in human MPS VI
fibroblasts as well as in affected tissues of an MPS VI
rodent model. In vivo, this was associated with inflamma-
tion and apoptosis. This adds to what has been observed
in other LSDs [8-16], where abnormal autophagy has
been described, proving that common mechanisms are
downstream of different genetic defects in LSDs. The
increased amount of autophagosomes in MPS VI fibrob-
lasts might be explained by the inability of lysosomes
engulfed with DS to recycle. Indeed, disruption of lyso-
some function inhibits the fulfillment of autophagy with
consequent massive accumulation of autophagosomes.
This is indirectly suggested by the slow EGF/EGFR turno-
ver observed in MPS VI fibroblasts. Interestingly, the EGF/
EGFR complex is recycled in lysosomes by cathepsin B
[26]. Glycosaminoglycans are reported to inhibit cathep-
sin activity [37] and cathepsin-activity deficiency results in
impaired autophagy [38].
Alterations in the autophagy-lysosomal degradation path-
way have been linked to normal brain aging [39], to age-
related neurodegenerative diseases including Alzheimer's
(AD) [40], Parkinson's (PD) [41], and Huntington's (HD)
diseases [42] in addition to several LSDs [8-16]. Since
deregulation of autophagy is associated with disease pro-
gression, it has been speculated that modulating
autophagy activity may result in therapeutic efficacy.
Enhancement of autophagy (that is, through treatment
with rapamycin) may help clear aggregated proteins, as
observed in neurodegenerative disorders [43]; however,
because autophagy relies on intact lysosomes for appro-
priate autophagosome-lysosome fusion, the progressive
impairment of lysosome function, as it occurs in LSDs,
may reverse any long-term benefits derived from the over-
Inflammation and apoptosis in visceral organs from MPS VI  affected rats Figure 4
Inflammation and apoptosis in visceral organs from 
MPS VI affected rats. (A) Immuno-histochemical analysis 
with anti-CD68 antibodies and (B) in situ TUNEL analyses of 
liver, spleen, and kidney sections from 6-month-old normal 
(NR) and affected (AF) rats. Magnification: 40×. (C) Apop-
totic cell count performed on liver, spleen, and kidney sec-
tions from 6-month-old NR and AF rats. *P ≤ 0.0001.
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Normal autophagy, ubiquitination, mitochondrial function, absence of inflammation, and apoptosis in MPS VI CNS without sig- nificant DS storage Figure 5
Normal autophagy, ubiquitination, mitochondrial function, absence of inflammation, and apoptosis in MPS VI 
CNS without significant DS storage. (A) Quantitative measurement of glycosaminoglycan (GAG) accumulation via dime-
thyl-methylene blue method on brain lysates of 6-month-old affected (AF) and normal (NR) rats. (GAG levels are expressed in 
μg per mg of proteins: μg GAG/mg prot). (B) Toluidine blue staining of semi-thin sections (1 μm thick) of brain from 6-month-
old AF and NR rats. Magnification: 100×. (C) Quantification of western blots performed on brain lysates from 6-month-old NR 
and AF rats. Values are expressed as fold of increase compared with NR rat brains (NR = 1) and are the mean ± standard 
error of three independent experiments. Western blot with anti-p62 antibodies did not allow the detection of any band in the 
brain of either NR or AF rats. (D) Immuno-histochemical analysis with anti-CD68 antibodies and (E)in situ TUNEL analysis of 
brain sections from 6-month-old NR and AF rats. Magnification: 100× and 20×, respectively. NS = not statistically significant; 
OB = olfactory bulb; MB = middle brain; BrSt = brain stem; Hipp = hippocampus; CB = cerebellum.
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stimulation of autophagy, resulting in nutrient starvation
and ultimately in autophagic cell death [44]. Indeed,
although induction of autophagy in AD has an initial pro-
tective role, long-term over-stimulation of autophagy
induces neuronal cell death. Conversely, inhibiting
autophagy either pharmacologically or via RNA interfer-
ence of specific genes significantly attenuates cell death in
AD and PD, respectively [40,45]. Therefore, agents that
attenuate autophagy might be similarly useful for treat-
ment of LSDs with increased levels of autophagic markers,
that is, NPC, GM1, and now, based on the results of this
study, MPS VI.
Although additional studies are required to prove the
mechanisms linking autophagy impairment to polyubiqui-
tination anomalies, mitochondrial dysfunction, inflamma-
tion, and apoptosis in MPS VI, some hypotheses can be
drawn. For instance, mitochondria produce metabolic
energy and free radicals (that is, reactive oxygen species
(ROS)), serve as biosensors for oxidative stress, and eventu-
ally become effectors of apoptosis [12,46]. In turn the accu-
mulation of fragmented mitochondria we have observed in
MPS VI cells and tissues may cause increasing oxidative
stress resulting in inflammation, which finally triggers cell
death responses as observed in different disorders [47].
Most importantly, our data support a strong association
between lysosomal storage and abnormal degradation
pathways, inflammation, and apoptosis in vivo. These were
present in liver, spleen, and kidney of MPS VI rats where we
detect significant DS storage and were absent in the CNS of
the same animals where DS storage is absent. In addition,
when DS storage is reduced in liver, spleen, and kidney fol-
lowing somatic AAV-mediated gene transfer, levels of
autophagic markers, polyubiquitinated proteins, frag-
mented mitochondria, inflammation, and apoptosis are
normalized, demonstrating a therapeutic efficacy on
autophagy deregulation and mitochondrial dysfunction in
addition to apoptosis and inflammation, as previously
described [30]. Similar data have been reported in cartilage
and synovial tissues of MPS VI rats, where authors ascribe
the onset of inflammation and apoptosis to gly-
cosaminoglycan storage [48,49]. Moreover, autophagic
markers, polyubiquitinated proteins, fragmented mito-
chondria, inflammation, and apoptosis can be used as
biomarkers for follow-up of disease progression. This may
be relevant to understanding the clinical history of the dis-
ease and to defining the endpoint assessment of therapeu-
tic regimens such as enzyme replacement therapy, bone
marrow transplantation, and gene therapy.
Conclusion
In this paper we have studied the relationship between
storage and secondary events, such as autophagy, polyu-
biquitination, mitochondrial function, inflammation,
and apoptosis, in MPS VI cells and tissues. We have dem-
onstrated a direct link between substrate storage and
abnormal cellular pathways which contribute to the
pathophysiology of MPS VI, and we have identified new
useful biomarkers for follow-up of disease progression.
Our data may help in the development of new therapies
which act downstream of the genetic defect in this and
other LSDs.
Methods
Tissue cultures, animal colonies, and tissue collection
Fibroblasts from MPS VI patients and from normal sub-
jects were grown at 37°C with 5% CO2, in RPMI (Gibco-
Invitrogen, Grand Island, NY, USA) and 10% fetal bovine
serum (FBS, Sigma-Aldrich, St Louis, MO, USA), supple-
mented with 100 U/ml penicillin, 100 μg/ml streptomy-
cin (Gibco-Invitrogen, USA). The cell lines were used
between passage 2 and 8, and maintained at the same pas-
sage number in each experiment performed.
Reduction of autophagic, ubiquitination, and mitochondrial  anomalies in livers of MPS VI rats following arylsulfatase B  gene transfer and DS normalization Figure 6
Reduction of autophagic, ubiquitination, and mito-
chondrial anomalies in livers of MPS VI rats following 
arylsulfatase B gene transfer and DS normalization. 
(A) Representative western blot analysis of tissue lysates 
from livers of 6-month-old NR and MPS VI rats treated (TR) 
or not (AF) with AAV. Membranes were blotted with anti-
BCN1, -LC3, -ubiquitin, -p62, -COX IV and -actin antibodies. 
(B) Quantification of western blots. Values are expressed as 
fold of increase compared with NR rat tissues (NR = 1) and 
are the mean of three independent experiments. *P ≤ 0.05, 
**P ≤ 0.01.
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MPS VI rats were maintained at the Cardarelli Hospital's
Animal House (Naples, Italy) in an appropriate environ-
ment according to the Italian Ministry of Health regula-
tion. Normal and affected offspring were obtained and
genotyped as previously described [30]. Tissues were col-
lected from 6-month-old rats in accordance to the Italian
Ministry of Health guidelines as previously described
[30]. Each tissue collected was divided in pieces and fixed
for plastic and paraffin embedding or frozen in dry ice for
ARSB activity, GAG quantitative assays, and protein
extraction.
Antibodies
Primary antibodies were: rabbit polyclonal anti-LC3
(Novus Biological, Littleton, Colorado, USA), rabbit pol-
yclonal anti-beclin 1 (Santa Cruz Biotechnology, Santa
Cruz, California, USA), goat monoclonal anti-LAMP2
(Santa Cruz Biotechnology, USA), mouse monoclonal
anti-ubiquitin (Cell Signaling, Danvers, Massachusetts,
USA), mouse monoclonal anti-P62/SQSTM1 (BD, Frank-
lin Lakes, New Jersey, USA), mouse monoclonal anti-actin
(Sigma-Aldrich, St Louis, Missouri, USA) and rabbit poly-
clonal anti-COXIV (Cell Signaling, USA). Secondary anti-
bodies were: goat anti-rabbit or anti-mouse conjugated to
Alexa Fluor 488 or 594 (Molecular Probes – Invitrogen,
Eugene, Oregon, USA). HRP-conjugated anti-mouse or
anti-rabbit IgG (Amersham, Freiburg, Germany); bioti-
nylated donkey anti-rabbit (Jackson ImmunoReasearch,
West Grove, Pennsylvania, USA).
Protein extraction and western blot analysis
Cells were lysed in cold lysis buffer (50 mM Tris-HCl, pH
7.5; 150 mM NaCl; 0.5% DOC; 0.5% NP-40; 2% sodium
azide) in the presence of protease (Roche Diagnostics,
Mannheim, Germany) and phosphatase (cocktails I and II
by Sigma-Aldrich, St Louis, Missouri, USA) inhibitors for
30 min on ice. Tissue samples (50 μg) were homogenized
in 3 volumes of lysis buffer and proteins were quantified
using the BCA protein assay reagent kit (Pierce Chemical
Co, Rockford, Illinois, USA) according to the manufac-
turer's instructions. Primary and (HRP)-conjugated anti-
bodies were diluted in 5% milk. Bands were visualized
using the ECL detection reagent (Pierce Chemical Co,
USA).
Confocal microscopy
A Leica inverted DMIRE2 epifluorescence microscope
equipped with a Leica laser-scanning confocal image sys-
tem TCS SP2 AOBS (Leica Microsystems, Heidelberg, Ger-
many) was used for data acquisition. Samples were
excited with a 488 nm Ar laser and 594 nm He-Ne laser.
Samples were vertically scanned from the bottom cover-
slip with a total depth of 50 mm and a 63× (1.32 NA) HP
PLAPO oil-immersion objective. A total of 10 z-line scans
with a step distance of 0.2 mm was collected and maxi-
mum intensity projections were generated with Leica
Confocal Software (Leica Microsystems, Wetzlar, Ger-
many).
EGF loading, time-lapse microscopy and immuno-
fluorescent analysis
For time-lapse microscopy, skin fibroblasts from normal
and MPS VI patients were plated in 35-mm glass-bottom
dishes (Willco BV, Amsterdam, the Netherlands) and were
incubated at 37°C in 5% CO2 for 16 h, after which they
where starved for 2 h with no-serum medium. Following
starvation, cells were loaded with 1 μg of Alexa Fluor 488-
labeled EGF (Molecular Probes, Invitrogen, USA) and 0.1
μM LysoTacker Red DND-99 (Molecular Probes, Invitro-
gen, USA) for 1 h at 4°C. After incubation, cells were
washed three times with 1 × PBS and medium was
replaced with fresh 10% FBS medium. Cells were
mounted on Leica AF6000 LX multiposition advanced flu-
orescence imaging and live cell analysis system (Leica
Microsystems, Wetzlar, Germany). The live imaging was
performed using an inverted microscope system (Leica
DMI6000; Leica, Heidelberg, Germany) equipped with
environment control boxes and digital camera (CCD).
Images were acquired in fluorescence (GFP and RFP) and
transmission (DIC) channels with a 63× glycerin-immer-
sion objective. Usually, stacks about 10 μm thick, com-
posed of sections separated by 0.22 μm, were taken every
15 min during an average period of 24 h. To avoid fading
of the fluorescence, the intensity levels were fixed at less
than position 2. The 4D captured images thus obtained
were deconvoluted using the blind algorithm and
adjusted using the brightness switch implemented in the
software package AF6000 (Leica, Heidelberg, Germany).
Maximum intensity projection of Z-stacks was done for
4D images. Online material (Additional files 1 and 2)
contains live-cell imaging.
For immuno-fluorescent microscopy, skin fibroblasts
from normal and MPS VI patients were plated in chamber
slides (LabTek International, Naperville, Illinois, USA)
and loaded with 1 μg of Alexa Fluor 488-labeled EGF
(Molecular Probes, Invitrogen, USA) as described above.
After washing, 10% FBS fresh medium was added onto
the cells, which were incubated at 37°C in 5% CO2, until
fixed at different time points with 4% PFA and mounted
with Vectashield with DAPI (Vector Laboratories, Burlin-
game, California, USA).
Mitochondrial membrane potential measurements
PBS-washed 1 × 106  cells were incubated in 1.3 nM
DiOC6 (Sigma-Aldrich, St Louis, Missouri, USA) and 1
mg/ml propidium iodide (PI, Sigma-Aldrich, St Louis,
Missouri, USA) for 15 min at 37°C. After washing, cells
were suspended in 1 ml PBS (pH 7.4) and were subse-
quently analyzed using flow cytometry. PI was used asPathoGenetics 2009, 2:4 http://www.pathogeneticsjournal.com/content/2/1/4
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counterstain to exclude dead cells from the analyses. At
least 10,000 cells in both normal and MPS VI were ana-
lyzed for each sample. The experiments were performed in
triplicate, and all statistical analyses were performed using
Stat-View 5.0 (Statsoft, Tulsa, Oklahoma, USA).
Assay of proteasome activity
20S proteasome activity was assayed on total lysates of
cultured fibroblasts and rat tissues (liver, spleen, kidney,
and brain) using the Chemicon (Temecula, California,
USA) assay kit, according to the manufacturer's recom-
mended protocol.
Semi-thin sections and immuno-histochemistry
For semi-thin sections, tissues were collected and fixed in
2.5% PFA and 2% glutaraldehyde for 12 h; post-fixed in
osmium tetroxide, block stained with 1% uranyl acetate,
dehydrated in ethanol, and embedded in plastic. Semi-
thin sections (1 μm thick) were stained with 0.1% toluid-
ine blue (Fisher Scientific, Pittsburgh, Pennslyvania,
USA). For immuno-histochemistry, tissues were fixed in
4% PFA for 12 h and embedded in paraffin (Sigma-
Aldrich, St Louis, Missouri, USA) after their dehydration
with a 70% to 100% ethanol gradient. Finally, the tissues
were sectioned to 5 μm serial sections on a microtome.
CD68 staining was performed as previously described
[30].
Electron microscopy analysis
Animal tissues (brains and livers) were fixed with 1% glu-
taraldehyde, washed, stained with uranylacetate and
OsO4, dehydrated in ethanol and embedded in Epon.
Resin blocks were sectioned using Ultracut UCT ultrami-
crotome (Leica Microsystems, Wetzlar, Germany). EM
images were acquired from thin sections under a Philips
Tecnai-12 electron microscope (Philips, Eindhoven, the
Netherlands) using an ULTRA VIEW CCD digital camera
(Soft Imaging Systems GmbH, Münster, Germany).
Quantitative analysis of GAG accumulation in tissues and 
urine
The urine and the protein extracts were assayed with the
dimethylmethylene blue-based spectrophotometry of gly-
cosaminoglycans. Briefly, tissues were homogenized in
water and centrifuged. After protein quantification, 10 μg
of protein extracts or 5 μl of urine were used for the color-
imetric assay as previously described [30]. The samples
were read at 520 nm and the GAG concentrations were
determined using the dermatan sulfate standard curve
(Sigma-Aldrich, St Louis, Missouri, USA). Tissue GAG was
expressed as μg GAG/mg protein.
TUNEL assay
TUNEL assay was performed on 5-μm fixed liver sections.
Apoptotic cells were detected by using the ApopTag In Situ
Apoptosis Detection Kit (Chemicon-Millipore, Temecula,
California, USA), as previously described [30].
Statistical analysis
Data were analyzed by one-way ANOVA (analysis of vari-
ance) and are expressed as the mean ± standard error. For
all statistical testing, a P value less than 0.05 was consid-
ered significant.
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